Detecting Drugs of Abuse Via Exhaled Breath Samples Using Differential Mobility Spectrometry

CompletedOBSERVATIONAL
Enrollment

32

Participants

Timeline

Start Date

August 1, 2021

Primary Completion Date

March 19, 2024

Study Completion Date

August 15, 2024

Conditions
Opiate AbuseMarijuana AbuseDiagnostic
Interventions
DRUG

Marihuana

Two doses of marijuana given.

DEVICE

BID2 Instrument - breathalyzer

The commercial device that we will be testing is designed to detect breath cannabinoid concentrations utilizing Differential Mobility Spectrometry technology, and was developed by Draper, to detect a wide range of chemicals and organisms in breath. Differential Mobility Spectrometry (DMS) is a robust, data-rich, ultra-trace, chemical detection technology. Unlike gas chromatography mass spectroscopy (GCMS) systems that are large and expensive, DMS is small, portable (approximately the size of a shoe box) and is able to measure the presence of volatile organic compounds (VOC) at parts per trillion (ppt) detection levels. The participant will exhale into the device via a plastic tube and the breath sample will be analyzed in situ. The participant does not come in contact with the device itself-they will simply exhale into a tube via a disposable mouthpiece.

Trial Locations (1)

02478

McLean Hospital, Belmont

All Listed Sponsors
collaborator

VOX BIOMEDICAL LLC

UNKNOWN

lead

Mclean Hospital

OTHER

NCT05384470 - Detecting Drugs of Abuse Via Exhaled Breath Samples Using Differential Mobility Spectrometry | Biotech Hunter | Biotech Hunter